



CELLULAR THERAPY

WALLET CARD

Chimeric antigen receptor (CAR) T-cell therapy can cause severe and life-threatening side effects. CAR T therapy that has been approved by the U.S. Food and Drug Administration (FDA) must follow guidelines called Risk Evaluation and Mitigation Strategies (REMS). The REMS program requires patients who have recently received CAR T therapy to carry a card in their wallet with information about their treatment.

Patients receiving products approved by the FDA must use the wallet card provided by the manufacturer who makes the CAR T therapy. Currently, cards for the medications Kymriah, Tecartus, and Yescarta are available:

- Kymriah (tisagenlecleucel): www.kymriah-rems.com
- Tecartus (brexucabtagene autoleucel): www.yescartatecartusrems.com
- Yescarta (axicabtagene ciloleucel): www.yescartatecartusrems.com

New cellular therapies are being developed. Contact your healthcare team if your treatment is not listed above.

If you are receiving CAR T therapy that does *not* come with a wallet card (for example, you are receiving treatment as part of a clinical trial), you can use the card below. Fill out the information requested (ask your cancer team if you need help), print out the card, and carry it in your wallet.

You should show the card to members of your healthcare team who are not treating your cancer, like an emergency room staff member or your primary care provider, so they know to look out for special issues related to your CAR T therapy.

HEALTHCARE PROVIDER ALERT: CAR T THERAPY PATIENT	HEALTHCARE PROVIDER ALERT: CAR T THERAPY PATIENT
Patient's Name: _____	Cancer Physician's Name: _____
Patient's Phone Number: _____	Office Phone Number: _____
Cancer Type: _____	After-Hours Phone Number: _____
Therapy: _____	<p>To the patient: CAR T therapy can cause severe and life-threatening side effects. Call your oncologist or go to the emergency room immediately if you experience any of these symptoms: fever (100.4 °F/38 °C or higher), difficulty breathing, low blood pressure, chills or shaking, confusion, headache, dizziness, lightheadedness, nausea, vomiting, or diarrhea.</p>
Date of last CAR T therapy treatment: _____	<p>To the healthcare provider: Contact the oncologist (1) before giving corticosteroids, (2) if the patient has a serious infection, or (3) if the patient must undergo an invasive procedure.</p>
<p><i>To the patient: For at least 4 weeks after your CAR T therapy treatment, you should stay within 2 hours of the location where you received it.</i></p>	